Gilead Sciences, Inc.

Cv Therapeutics, Inc.

Other

The Endowment for Research in Human Biology, Inc.

Robert H Jiang

Jeff A Zablocki

Elfatih O Elzein

Thao Perry

Xiaofen Li

Britton Kenneth Corkey

Dmitry Koltun

Rao V Kalla

Ruben Martinez

Eric Q Parkhill

Tetsuya Kobayashi

Matthew Abelman

Michael Graupe

Chandrasekar Venkataramani

Juan A Guerrero

Prabha N Ibrahim

Gregory Notte

Kevin D Shenk

Christopher F Morrison

Hai Yang

David Sperandio

Jinfa Du

Michael R Mish

Samuel E Metobo

Gregory F Chin

Evangelos Aktoudianakis

Kristyna M Elbel

Sophie Shevick

Rick Andrew Lee

Dengming Xiao

Manuel Munoz

Nancy Chu

Kwan Leung

Venkata Poornapragnacharyulu Palle

Richard M Lawn

Kerim Babaoglu

Michael G Campbell

Tim Marquart

Michael Organ

Wing Ming Keung

Yaroslav Bilokin

Guoxin Tao

Ivan Diamond

Melanie Boze

William Shirley

Reina Natero

Zhan Jiang

Maria Pia Arolfo

Peidong Fan

Lina Yao

Rick Lee

Kristyna Elbel

Michael Mish

Gregory Chin

This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R, R, R, R, R, R, R, and Rare described herein.

Benzimidazole derivatives as bromodomain inhibitors

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Y, Z, n, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Fused heterocyclic compounds as ion channel modulators

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R, X, X, Y and Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Z, Z, Z, Z, X, Y, R, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W, W, W, R, Q, X, Xand Xare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R, R, R, R, R, and X are described herein.

Benzimidazolone derivatives as bromodomain inhibitors

This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula I wherein R, R, R, R, R, W, X, and Z are as described herein.

Quinoline derivatives as bromodomain inhibitors

The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.

Substituted heterocyclic compounds

The present invention relates to sodium channel inhibitors of Formula I: in which R, R, R, R, R, R, and Rare as defined above, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes.

Growing community of inventors

Cupertino, CA, United States of America

Robert H Jiang